Inventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts

Shares of Inventiva S.A. (NASDAQ:IVA) have been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $17.00.

Several equities research analysts have weighed in on the company. Lifesci Capital reissued an “outperform” rating on shares of Inventiva in a research note on Friday, January 5th. Stifel Nicolaus cut their target price on Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Inventiva in a research report on Monday, April 1st. Finally, Canaccord Genuity Group boosted their price objective on shares of Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, April 8th.

Institutional Investors Weigh In On Inventiva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Commonwealth Equity Services LLC increased its position in shares of Inventiva by 20.5% during the third quarter. Commonwealth Equity Services LLC now owns 24,435 shares of the company’s stock worth $103,000 after acquiring an additional 4,155 shares during the period. Citigroup Inc. increased its holdings in Inventiva by 91.7% during the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock worth $84,000 after purchasing an additional 11,000 shares during the period. Finally, Morgan Stanley raised its position in Inventiva by 300.0% during the 4th quarter. Morgan Stanley now owns 6,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,500 shares in the last quarter. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

Inventiva stock opened at $3.31 on Friday. The company’s 50-day moving average price is $3.68 and its 200-day moving average price is $3.93. Inventiva has a twelve month low of $2.22 and a twelve month high of $5.05.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.